EyeConic: Qualification for Cone-Optogenetics

a study on Retinal Dystrophy

Summary

Healthy Volunteers
healthy people welcome
Location
at San Francisco, California and other locations
Dates
study started
completion around
Principal Investigator
by Jacque Duncan, MD
Headshot of Jacque Duncan
Jacque Duncan

Description

Summary

This study aims to prepare for the first-in-human clinical trial of cone optogenetics vision restoration. As a first step, this worldwide multicenter ocular imaging study (EyeConic Study) is performed to identify eligible patients.

Official Title

Qualification for Cone-Optogenetics (EyeConic)

Details

In a subset of patients with inherited retinal dystrophies (IRDs), cones lose their light-sensitive outer segments but remain alive in a dormant stage. This creates an opportunity to resensitize them through targeted optogenetic tools. However, the true proportion of low vision patients harboring dormant, non-functional cones, is currently unknown. The worldwide multicenter retrospective study (EyeConic) aims to estimate the proportion of low vision patients with remaining cone cell bodies for the first time.

Keywords

Retinal Dystrophies, Cone-Optogenetics, Rod-cone Dystrophy, Cone-rod Dystrophy, Generalized retinal dystrophies, Inherited retinal disease, Optical coherence tomography (OCT)

Eligibility

You can join if…

(patients):

  • Diagnosis of generalized IRD
  • Low vision as defined as visual acuity worse or equal to 0.05 (or 20/400) in the study eye
  • Availability of macular optical coherence tomography (OCT)

Inclusion Criteria (controls):

  • Normal ophthalmic findings
  • Availability of macular optical coherence tomography (OCT)

You CAN'T join if...

(all):

  • Other eye diseases with a significant effect on vision or retinal structure
  • Extraocular disease affecting retinal structure such as neurodegenerative diseases

Locations

  • UCSF, Department of Ophthalmology accepting new patients
    San Francisco California 94158 United States
  • University of Pittsburgh, Department of Ophthalmology accepting new patients
    Pittsburgh Pennsylvania 15213 United States

Lead Scientist at UCSF

  • Jacque Duncan, MD
    Retinitis pigmentosa (RP) affects about 1 in 3,500 people worldwide. Age-related macular degeneration (AMD) affects as many as 1 in 4 people by the age of 75 and is the leading cause of blindness in people over age 50 in the United States. Both RP and AMD have a hereditary basis, and currently, there is no cure for either of these types of hereditary retinal degeneration.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University Hospital, Basel, Switzerland
ID
NCT05294978
Study Type
Observational
Participants
Expecting 1000 study participants
Last Updated
Contact us about this trial